Alzheimer's drug offers a glimpse of efficacy

A mid-stage compound named NIC5-15 has shown promise as a safe and efficacious therapy for stabilizing the cognitive impairment experienced by Alzheimer's patients, according to researchers from Mount Sinai School of Medicine.

Phase IIA preliminary clinical findings--presented at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease in Vienna on Sunday--demonstrated the drug's ability to prevent the formation of beta-amyloid, a substance that has been shown to build up in the brains of patients suffering from dementia. And the study lays the foundation for a Phase IIb clinical trial scheduled for launch later this year with funding from the NIH.

"NIC5-15 is part of a new class of natural compound we found to have the potential of precluding the generation of β-amyloid and, eventually, attenuating cognitive deterioration in preclinical models of Alzheimer's disease," said Dr. Hillel Grossman, clinical director of the Mount Sinai Memory and Aging Center. Minneapolis, MN-based Humanetics Corporation has exclusive rights to develop and commercialize NIC5-15 to treat Alzheimer's disease.

Investigators involved in the study gathered preliminary evidence of treatment efficacy, including activities of daily living, behavioral disturbances, pharmacokinetic parameters and a number of Alzheimer's disease biomarkers including Abeta peptide levels. Patients were given escalating oral doses of NIC5-15 over a 45-day period.

- check out the release from researchers
- read the announcement from Humanetics

Suggested Articles

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.

Merck will apply its vaccine capabilities to an asset based on Themis’ measles vector platform that is set to enter the clinic this year.